[{"orgOrder":0,"company":"Shandong University","sponsor":"The Affiliated Hospital of Qingdao University | The People's Hospital of Guangrao | Weihai Municipal Hospital | Shandong Province Third Hospital | Taian City Central Hospital | Jining No.2 People's Hospital | Maternity and Child Care Health Center of Dezh","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shandong University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong University \/ The Affiliated Hospital of Qingdao University | The People's Hospital of Guangrao | Weihai Municipal Hospital | Shandong Province Third Hospital | Taian City Central Hospital | Jining No.2 People's Hospital | Maternity and Child Care Health Center of Dezh","highestDevelopmentStatusID":"11","companyTruncated":"Shandong University \/ The Affiliated Hospital of Qingdao University | The People's Hospital of Guangrao | Weihai Municipal Hospital | Shandong Province Third Hospital | Taian City Central Hospital | Jining No.2 People's Hospital | Maternity and Child Care Health Center of Dezh"},{"orgOrder":0,"company":"Shandong University","sponsor":"Maternity and Child Care Health Center of Dezhou | Heze Municipal 3rd people's hospital | Peking University Care Luzhong Hospital | The People's Hospital of Jimo.Qingdao","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shandong University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong University \/ Maternity and Child Care Health Center of Dezhou | Heze Municipal 3rd people's hospital | Peking University Care Luzhong Hospital | The People's Hospital of Jimo.Qingdao","highestDevelopmentStatusID":"11","companyTruncated":"Shandong University \/ Maternity and Child Care Health Center of Dezhou | Heze Municipal 3rd people's hospital | Peking University Care Luzhong Hospital | The People's Hospital of Jimo.Qingdao"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Hospital, Nancy, France \/ Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"6","companyTruncated":"Central Hospital, Nancy, France \/ Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"Helse Stavanger","sponsor":"Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Helse Stavanger","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Helse Stavanger \/ Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway","highestDevelopmentStatusID":"11","companyTruncated":"Helse Stavanger \/ Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kaizen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"||Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kaizen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Gaelan Medical"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Phil"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Entera Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Evonik","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evonik \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Evonik \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.26000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Amoxine
Details :
Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Details :
Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Details :
LP-001 (amoxicillin/clavulanate) oral suspension is currently being investigated as an effective antimicrobial for the treatment of children with acute otitis media in 3-12 moth age pediatric.
Details :
Amoxicillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Erythema Chronicum Migrans.
Details :
Amoxicillin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Severe Acute Malnutrition.
Details :
VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB) co-packaged with antibiotics. It has been approved by FDA for the treatment of H. pylori infection in a...
Details :
Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.
Sponsor :
Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway
Sponsor :
Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway
Details :
Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics and a proton pump inhibitor (PPI) (omeprazole), used for the treatment of H. pylori infection.
Details :
Under the agreement, RedHill will make Talicia, a novel, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole magnesium), approved for H. pylori infection, available via the PhilRx Pat...
Reset All
Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!
